13,668 Shares in STAAR Surgical (NASDAQ:STAA) Acquired by XTX Topco Ltd

XTX Topco Ltd acquired a new stake in STAAR Surgical (NASDAQ:STAA) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 13,668 shares of the medical instruments supplier’s stock, valued at approximately $508,000.

A number of other institutional investors have also recently made changes to their positions in the stock. State Street Corp increased its stake in shares of STAAR Surgical by 0.5% in the third quarter. State Street Corp now owns 1,940,567 shares of the medical instruments supplier’s stock worth $72,092,000 after buying an additional 10,430 shares during the period. Geneva Capital Management LLC increased its position in shares of STAAR Surgical by 0.3% in the third quarter. Geneva Capital Management LLC now owns 695,415 shares of the medical instruments supplier’s stock valued at $25,835,000 after acquiring an additional 2,241 shares during the period. Defender Capital LLC. raised its stake in shares of STAAR Surgical by 4.4% during the third quarter. Defender Capital LLC. now owns 677,617 shares of the medical instruments supplier’s stock valued at $25,173,000 after acquiring an additional 28,430 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC boosted its holdings in shares of STAAR Surgical by 50.1% during the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 592,621 shares of the medical instruments supplier’s stock worth $28,215,000 after purchasing an additional 197,717 shares during the period. Finally, American Capital Management Inc. grew its stake in shares of STAAR Surgical by 42.9% in the third quarter. American Capital Management Inc. now owns 512,813 shares of the medical instruments supplier’s stock worth $19,051,000 after purchasing an additional 154,037 shares during the last quarter. Hedge funds and other institutional investors own 96.70% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on STAA shares. Canaccord Genuity Group lowered their price target on STAAR Surgical from $31.00 to $28.00 and set a “hold” rating for the company in a research report on Monday, December 9th. Stifel Nicolaus decreased their target price on STAAR Surgical from $50.00 to $44.00 and set a “buy” rating for the company in a report on Monday, August 26th. Stephens upgraded shares of STAAR Surgical to a “hold” rating in a report on Monday, December 2nd. Finally, Needham & Company LLC reissued a “hold” rating on shares of STAAR Surgical in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $42.83.

STAAR Surgical Trading Down 2.1 %

STAA opened at $24.86 on Friday. The company has a market cap of $1.23 billion, a price-to-earnings ratio of 56.50 and a beta of 0.59. The stock has a fifty day simple moving average of $28.91 and a two-hundred day simple moving average of $35.01. STAAR Surgical has a 12-month low of $24.21 and a 12-month high of $52.68.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.